SAVA Profile
Cassava Sciences, Inc., based in Austin, Texas, operates as an innovative clinical-stage biotechnology firm specializing in the development of novel therapies for neurodegenerative diseases. Established in 1998 and rebranded from its previous identity as Pain Therapeutics, Inc. in March 2019, the company is dedicated to advancing treatments that target debilitating conditions affecting the central nervous system.
At the forefront of Cassava Sciences, Inc.'s portfolio is simufilam, its lead therapeutic product candidate. This small molecule drug has completed Phase 2b clinical trials, demonstrating promising results in its potential to address neurodegenerative disorders such as Alzheimer's disease. The company's commitment to advancing simufilam underscores its focus on pioneering innovative solutions that address significant unmet medical needs in aging populations.
In addition to therapeutic advancements, Cassava Sciences, Inc. is actively developing SavaDx, an investigational diagnostic product candidate. SavaDx represents a groundbreaking blood-based biomarker designed to detect early stages of Alzheimer's disease, offering potential diagnostic capabilities that could revolutionize disease management and patient care. The company's integrated approach combines cutting-edge research with clinical expertise to drive forward-thinking solutions in the field of neurodegenerative diagnostics.
Located in Austin, Texas, Cassava Sciences, Inc. strategically positions itself within a thriving biotechnology ecosystem, fostering collaborations and partnerships to accelerate the development and commercialization of its pipeline. The company's visionary leadership and dedication to scientific innovation underscore its pivotal role in shaping the future of neurology and enhancing quality of life for patients worldwide affected by neurodegenerative diseases.
|
